MHRA Medical Devices Exceptional Use Authorisations List Updated

The UK's MHRA has updated its list of medical devices granted exceptional use authorisations. This guidance document provides transparency on manufacturers and devices that have received exemptions, including those whose authorisations have expired or been cancelled.

MHRA: Stop using non-sterile alcohol-free wipes due to infection risk

The MHRA and UKHSA are advising the public not to use four specific non-sterile alcohol-free wipe products due to contamination with Burkholderia stabilis bacteria. These products have been withdrawn from sale, but may still be in homes, and are linked to 59 cases, including one death.

MHRA: Quetiapine Oral Suspension Recalled Due to Incorrect Active Ingredient

The MHRA has issued a recall for all batches of quetiapine oral suspension manufactured by Eaststone Limited due to an incorrect amount of the active ingredient, potentially leading to overdose. Approximately 166 bottles manufactured between October 2025 and January 2026 are affected. Patients are advised not to stop medication without consulting a healthcare professional.

MHRA Updates GLP-1 Guidance on Pancreatitis Risk

The MHRA has updated product information regarding the small risk of severe acute pancreatitis associated with GLP-1 medications. Healthcare professionals and patients are reminded to be alert to symptoms, and the MHRA is investigating genetic factors influencing this risk.

MHRA Updates Semaglutide Guidance on NAION Risk

The MHRA has updated its guidance for semaglutide prescribers and patients regarding the very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION). The update alerts healthcare professionals and patients to the symptoms and advises immediate medical attention if vision changes occur. This guidance follows three reports of NAION associated with semaglutide since 2018.

FTC Sending $22.8 Million to Consumers for Deceptive Real Estate Schemes

The FTC is returning nearly $23 million to 1,659 consumers who were defrauded by deceptive real estate schemes, specifically Sanctuary Belize and Kanantik. This second distribution includes checks averaging $16,462 for Sanctuary Belize investors and $6,346.39 for Kanantik investors.

FTC Settlement with Express Scripts to Lower Drug Costs

The FTC has secured a settlement with Express Scripts, Inc. (ESI), a major pharmacy benefit manager, requiring significant changes to its business practices. These changes are projected to lower drug costs for patients by up to $7 billion over 10 years and increase revenue for community pharmacies.

FTC ANPRM on Rental Housing Fees Submitted to OMB

The FTC has submitted a draft Advance Notice of Proposed Rulemaking (ANPRM) concerning fees in the rental housing market to the Office of Management and Budget (OMB) for review. This action signals the agency's intent to potentially create new rules to address deceptive or unfair fees charged to renters.

FTC Draft Rulemaking on Negative Option Plans Submitted for Review

The FTC has submitted a draft Advance Notice of Proposed Rulemaking (ANPRM) concerning its Negative Option Rule to the Office of Management and Budget (OMB) for review. This action indicates the agency is considering potential revisions or new regulations related to negative option plans, which are common in subscription services.

FTC Warns 42 Law Firms on Anticompetitive DEI Hiring Practices

The FTC has issued warning letters to 42 law firms regarding potentially anticompetitive employment practices related to Diversity, Equity, and Inclusion (DEI) hiring. The firms, which participated in the Mansfield Certification program, are cautioned that coordinating on candidate pools or sharing pay information may violate antitrust laws.